Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
SAN DIEGO, April 17, 2018 -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report first quarter 2018 financial results on Tuesday, May 1, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
| Conference Call Information | ||
| Date: | Tuesday, May 1, 2018 | |
| Time: | 4:30 p.m. ET | |
| Dial-in numbers: | +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) | |
| Confirmation code: | 1169697 | |
| Live webcast: | Retrophin.com in the “Events & Presentations” section of the “Investors” page | |
A replay of the call will be available from 7:30 p.m. ET, May 1, 2018 to 7:30 p.m. ET, May 8, 2018. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 1169697.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare diseases. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including a joint development arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to neurological and behavioral impairment. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam® and Thiola®.
Contact:
Chris Cline, CFA
Vice President, Investor Relations & Corporate Communications
646-564-3680
[email protected]
